CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 277 enrolled
Drug / intervention
niacin extended-release (NER) +2 moredrug
Likely dose
niacin extended-release (NER) 2000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00626392
NCT00626392Phase 3Completed
CompareCT.gov

Multicenter, Randomized, Double-Blind, Parallel, Acetylsalicylic Acid (ASA) Run-In Study to Evaluate the EFFECTS of Acetylsalicylic Acid on Niaspan®-Induced Flushing in Subjects With Dyslipidemia

Abbott·interventional·Posted Feb 29, 2008·Updated Sep 2, 2009

In Brief

A Phase 3 clinical trial evaluating niacin extended-release (NER), aspirin (ASA), and 1 other intervention for Dyslipidemia. Completed, enrolled 277 participants across 26 sites.

Detailed Summary

The primary purpose of this study was to assess the effect of aspirin (ASA) on niacin extended-release (NER)-induced flushing in subjects with dyslipidemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 29, 2008
Enrollment StartFeb 1, 2008
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.3 years ago

Interventions

niacin extended-release (NER)drug

Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period

aspirin (ASA)drug

325 mg tablets administered once daily

aspirin placebo (ASA Pbo)drug

Tablets administered once daily